BrainStorm Cell Therapeutics Reports Q3 Financial Results and Updates on NurOwn® Program

News related to:BrainStorm Cell Therapeutics Inc · 3 min read
NEW YORK, Nov. 16, 2026 /CourierPR/ -- BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, has announced financial results for the third quarter ended September 30, 2026, and provided a corporate update. The company continues to advance its NurOwn® (MSC-NTF cells) program for the treatment of amyotrophic lateral sclerosis (ALS), a devastating disease with a critical unmet medical need.
The company is working diligently to prepare for the initiation of the Phase 3b ENDURANCE study of NurOwn® in earlier-stage ALS patients, supported by an FDA-agreed Special Protocol Assessment (SPA).
In a significant corporate development, Professor Peter J. Pitts, a former FDA Associate Commissioner and co-founder of the Center for Medicine in the Public Interest, was appointed as Executive Chairman on July 28, 2026. Professor Pitts, who joined the Board in May 2026, is now leading the Company's daily operations, partnerships, investor engagement, and regulatory strategy, focusing primarily on advancing the Phase 3b ENDURANCE trial. Professor Jacob Frenkel, a member of BrainStorm's leadership team since 2007 and Board Chairman since 2020, transitioned to Senior Advisor.
During the third quarter, BrainStorm's leadership participated in the 31st Dubai International Pharmaceuticals & Technologies Conference and Exhibition (DUPHAT) in Dubai. CEO Chaim Lebovits and Executive Chairman Professor Peter J. Pitts delivered keynote addresses and moderated panel sessions on regulatory science harmonization and translational collaboration. The company also met with regional health regulators, commercial distribution partners, and international investment groups to discuss the strategic positioning of NurOwn® and the planned Phase 3b ENDURANCE trial.
Financially, BrainStorm reported a cash position of approximately $0.35 million as of September 30, 2026, compared to $0.24 million as of September 30, 2025. Research and development expenditures for the third quarter of 2026 were approximately $0.5 million, down from $0.9 million in the same period of 2025. General and administrative expenses for the third quarter of 2026 were approximately $1.09 million, compared to $1.15 million in the third quarter of 2025. Net loss for the third quarter of 2026 was approximately $1.7 million, compared to a net loss of approximately $2.1 million for the third quarter of 2025. Net loss per share for the third quarters of 2026 and 2025 was $(0.14) and $(0.19), respectively.
The NurOwn® technology platform, which uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), has generated valuable insights into ALS disease biology. BrainStorm's R&D team published a peer-reviewed study in Stem Cell Research & Therapy, a Q1-ranked journal (DOI: 10.1186/s13287-026-05303-y), demonstrating the beneficial effects of small extracellular vesicles derived from MSC-NTF cells on lung inflammation and fibrosis. The study showed reduced lung inflammation and fibrosis, improved oxygenation, and protection against subsequent lung injury following inhaled pretreatment in preclinical models.
BrainStorm's NurOwn® clinical program includes a completed Phase 3 trial in ALS (NCT03280056) and a second Phase 3b trial set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The company has also completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging area of regenerative medicine.